Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene

Variability of thrombotic disease among individuals homozygous for factor V Leiden has been described. It has been shown that some thrombotic patients carry an additional genetic risk factor such as protein C, protein S, antithrombin deficiency or the G20210A mutation on the prothrombin gene. The oc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood coagulation & fibrinolysis 2000-12, Vol.11 (8), p.761-765
Hauptverfasser: Magdelaine, A, Verdy, E, Coulet, F, Berkane, N, Girot, R, Uzan, S, Soubrier, F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 765
container_issue 8
container_start_page 761
container_title Blood coagulation & fibrinolysis
container_volume 11
creator Magdelaine, A
Verdy, E
Coulet, F
Berkane, N
Girot, R
Uzan, S
Soubrier, F
description Variability of thrombotic disease among individuals homozygous for factor V Leiden has been described. It has been shown that some thrombotic patients carry an additional genetic risk factor such as protein C, protein S, antithrombin deficiency or the G20210A mutation on the prothrombin gene. The occurrence of a deep vein thrombosis during enoxaparin prophylactic treatment in a pregnant woman homozygous for factor V Leiden, without other known prothrombotic genetic factors, led us to investigate her thrombomodulin gene. We found that the patient was heterozygous for the previously described G ← A mutation, which results in an Ala ← Thr substitution. Furthermore, for this patient, the allelic combination at the 1418 polymorphic site was C/T, which predicts an Ala ← Val replacement. Although larger studies are required, this case report suggests that thrombomodulin gene mutations could be an additional genetic risk factor for thrombosis in carriers of the factor V Leiden mutation.
doi_str_mv 10.1097/00001721-200012000-00010
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00001721_200012000_00010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11132655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3840-183584f0ff63e29830b12c5078fd01f514a306cb4e6ae654a0131c58ecd727d83</originalsourceid><addsrcrecordid>eNp1ks9u1DAQxi0EokvhFZAlzgH_jb3HqkBBWokLcI28zngTSOzIdtguD8C5T9SH4UlwutvCBR88o_HvG43mM0KYkteUrNUbUg5VjFZsSZarWhLyCK2oULySivPHaEXWUlWScXmGnqX0rSBcaPUUnVFKOaulXKHbtwAT_gG9x7mLYdyG1CfczrH3Oww-XJvJlBxPMUzdYTA29xbnCCaP4DMuLwYfwlzgKcLOm1Lbh9F43IUx_DzswpywCxG7oizhK95A30JR-RZ3kCH-C-UO8BVlCv_-dYMv8Dhnk_vg8d1wcD_gGNp5KKUdeHiOnjgzJHhxiufoy_t3ny8_VJtPVx8vLzaV5VqQimoutXDEuZoDW2tOtpRZSZR2LaFOUmE4qe1WQG2glsIQyqmVGmyrmGo1P0f62NfGkFIE10yxH008NJQ0iyXNvSXNgyXNnSVF-vIonebtCO1f4cmDArw6ASZZM7hovO3TA6clE2xpI47UPgxlben7MO8hNh2YIXfN_z4E_wPPCacZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>Magdelaine, A ; Verdy, E ; Coulet, F ; Berkane, N ; Girot, R ; Uzan, S ; Soubrier, F</creator><creatorcontrib>Magdelaine, A ; Verdy, E ; Coulet, F ; Berkane, N ; Girot, R ; Uzan, S ; Soubrier, F</creatorcontrib><description>Variability of thrombotic disease among individuals homozygous for factor V Leiden has been described. It has been shown that some thrombotic patients carry an additional genetic risk factor such as protein C, protein S, antithrombin deficiency or the G20210A mutation on the prothrombin gene. The occurrence of a deep vein thrombosis during enoxaparin prophylactic treatment in a pregnant woman homozygous for factor V Leiden, without other known prothrombotic genetic factors, led us to investigate her thrombomodulin gene. We found that the patient was heterozygous for the previously described G ← A mutation, which results in an Ala ← Thr substitution. Furthermore, for this patient, the allelic combination at the 1418 polymorphic site was C/T, which predicts an Ala ← Val replacement. Although larger studies are required, this case report suggests that thrombomodulin gene mutations could be an additional genetic risk factor for thrombosis in carriers of the factor V Leiden mutation.</description><identifier>ISSN: 0957-5235</identifier><identifier>EISSN: 1473-5733</identifier><identifier>DOI: 10.1097/00001721-200012000-00010</identifier><identifier>PMID: 11132655</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>Adult ; Anticoagulants - adverse effects ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Enoxaparin - administration &amp; dosage ; Enoxaparin - adverse effects ; Factor V - genetics ; Female ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Point Mutation ; Pregnancy ; Pregnancy Complications, Cardiovascular - prevention &amp; control ; Thrombomodulin - genetics ; Thrombophlebitis - chemically induced ; Thrombophlebitis - genetics</subject><ispartof>Blood coagulation &amp; fibrinolysis, 2000-12, Vol.11 (8), p.761-765</ispartof><rights>2000 Lippincott Williams &amp; Wilkins, Inc.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3840-183584f0ff63e29830b12c5078fd01f514a306cb4e6ae654a0131c58ecd727d83</citedby><cites>FETCH-LOGICAL-c3840-183584f0ff63e29830b12c5078fd01f514a306cb4e6ae654a0131c58ecd727d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=852420$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11132655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magdelaine, A</creatorcontrib><creatorcontrib>Verdy, E</creatorcontrib><creatorcontrib>Coulet, F</creatorcontrib><creatorcontrib>Berkane, N</creatorcontrib><creatorcontrib>Girot, R</creatorcontrib><creatorcontrib>Uzan, S</creatorcontrib><creatorcontrib>Soubrier, F</creatorcontrib><title>Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene</title><title>Blood coagulation &amp; fibrinolysis</title><addtitle>Blood Coagul Fibrinolysis</addtitle><description>Variability of thrombotic disease among individuals homozygous for factor V Leiden has been described. It has been shown that some thrombotic patients carry an additional genetic risk factor such as protein C, protein S, antithrombin deficiency or the G20210A mutation on the prothrombin gene. The occurrence of a deep vein thrombosis during enoxaparin prophylactic treatment in a pregnant woman homozygous for factor V Leiden, without other known prothrombotic genetic factors, led us to investigate her thrombomodulin gene. We found that the patient was heterozygous for the previously described G ← A mutation, which results in an Ala ← Thr substitution. Furthermore, for this patient, the allelic combination at the 1418 polymorphic site was C/T, which predicts an Ala ← Val replacement. Although larger studies are required, this case report suggests that thrombomodulin gene mutations could be an additional genetic risk factor for thrombosis in carriers of the factor V Leiden mutation.</description><subject>Adult</subject><subject>Anticoagulants - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Enoxaparin - administration &amp; dosage</subject><subject>Enoxaparin - adverse effects</subject><subject>Factor V - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Point Mutation</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Cardiovascular - prevention &amp; control</subject><subject>Thrombomodulin - genetics</subject><subject>Thrombophlebitis - chemically induced</subject><subject>Thrombophlebitis - genetics</subject><issn>0957-5235</issn><issn>1473-5733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ks9u1DAQxi0EokvhFZAlzgH_jb3HqkBBWokLcI28zngTSOzIdtguD8C5T9SH4UlwutvCBR88o_HvG43mM0KYkteUrNUbUg5VjFZsSZarWhLyCK2oULySivPHaEXWUlWScXmGnqX0rSBcaPUUnVFKOaulXKHbtwAT_gG9x7mLYdyG1CfczrH3Oww-XJvJlBxPMUzdYTA29xbnCCaP4DMuLwYfwlzgKcLOm1Lbh9F43IUx_DzswpywCxG7oizhK95A30JR-RZ3kCH-C-UO8BVlCv_-dYMv8Dhnk_vg8d1wcD_gGNp5KKUdeHiOnjgzJHhxiufoy_t3ny8_VJtPVx8vLzaV5VqQimoutXDEuZoDW2tOtpRZSZR2LaFOUmE4qe1WQG2glsIQyqmVGmyrmGo1P0f62NfGkFIE10yxH008NJQ0iyXNvSXNgyXNnSVF-vIonebtCO1f4cmDArw6ASZZM7hovO3TA6clE2xpI47UPgxlben7MO8hNh2YIXfN_z4E_wPPCacZ</recordid><startdate>200012</startdate><enddate>200012</enddate><creator>Magdelaine, A</creator><creator>Verdy, E</creator><creator>Coulet, F</creator><creator>Berkane, N</creator><creator>Girot, R</creator><creator>Uzan, S</creator><creator>Soubrier, F</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><general>The Scientist</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200012</creationdate><title>Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene</title><author>Magdelaine, A ; Verdy, E ; Coulet, F ; Berkane, N ; Girot, R ; Uzan, S ; Soubrier, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3840-183584f0ff63e29830b12c5078fd01f514a306cb4e6ae654a0131c58ecd727d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Anticoagulants - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Enoxaparin - administration &amp; dosage</topic><topic>Enoxaparin - adverse effects</topic><topic>Factor V - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Point Mutation</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Cardiovascular - prevention &amp; control</topic><topic>Thrombomodulin - genetics</topic><topic>Thrombophlebitis - chemically induced</topic><topic>Thrombophlebitis - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magdelaine, A</creatorcontrib><creatorcontrib>Verdy, E</creatorcontrib><creatorcontrib>Coulet, F</creatorcontrib><creatorcontrib>Berkane, N</creatorcontrib><creatorcontrib>Girot, R</creatorcontrib><creatorcontrib>Uzan, S</creatorcontrib><creatorcontrib>Soubrier, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood coagulation &amp; fibrinolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magdelaine, A</au><au>Verdy, E</au><au>Coulet, F</au><au>Berkane, N</au><au>Girot, R</au><au>Uzan, S</au><au>Soubrier, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene</atitle><jtitle>Blood coagulation &amp; fibrinolysis</jtitle><addtitle>Blood Coagul Fibrinolysis</addtitle><date>2000-12</date><risdate>2000</risdate><volume>11</volume><issue>8</issue><spage>761</spage><epage>765</epage><pages>761-765</pages><issn>0957-5235</issn><eissn>1473-5733</eissn><abstract>Variability of thrombotic disease among individuals homozygous for factor V Leiden has been described. It has been shown that some thrombotic patients carry an additional genetic risk factor such as protein C, protein S, antithrombin deficiency or the G20210A mutation on the prothrombin gene. The occurrence of a deep vein thrombosis during enoxaparin prophylactic treatment in a pregnant woman homozygous for factor V Leiden, without other known prothrombotic genetic factors, led us to investigate her thrombomodulin gene. We found that the patient was heterozygous for the previously described G ← A mutation, which results in an Ala ← Thr substitution. Furthermore, for this patient, the allelic combination at the 1418 polymorphic site was C/T, which predicts an Ala ← Val replacement. Although larger studies are required, this case report suggests that thrombomodulin gene mutations could be an additional genetic risk factor for thrombosis in carriers of the factor V Leiden mutation.</abstract><cop>Philadelphia, PA</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>11132655</pmid><doi>10.1097/00001721-200012000-00010</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0957-5235
ispartof Blood coagulation & fibrinolysis, 2000-12, Vol.11 (8), p.761-765
issn 0957-5235
1473-5733
language eng
recordid cdi_crossref_primary_10_1097_00001721_200012000_00010
source Journals@Ovid Ovid Autoload; MEDLINE
subjects Adult
Anticoagulants - adverse effects
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Enoxaparin - administration & dosage
Enoxaparin - adverse effects
Factor V - genetics
Female
Humans
Medical sciences
Pharmacology. Drug treatments
Point Mutation
Pregnancy
Pregnancy Complications, Cardiovascular - prevention & control
Thrombomodulin - genetics
Thrombophlebitis - chemically induced
Thrombophlebitis - genetics
title Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127 ← A mutation in the thrombomodulin gene
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T10%3A38%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deep%20vein%20thrombosis%20during%20enoxaparin%20prophylactic%20treatment%20in%20a%20young%20pregnant%20woman%20homozygous%20for%20factor%20V%20Leiden%20and%20heterozygous%20for%20the%20G127%20%E2%86%90%20A%20mutation%20in%20the%20thrombomodulin%20gene&rft.jtitle=Blood%20coagulation%20&%20fibrinolysis&rft.au=Magdelaine,%20A&rft.date=2000-12&rft.volume=11&rft.issue=8&rft.spage=761&rft.epage=765&rft.pages=761-765&rft.issn=0957-5235&rft.eissn=1473-5733&rft_id=info:doi/10.1097/00001721-200012000-00010&rft_dat=%3Cpubmed_cross%3E11132655%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11132655&rfr_iscdi=true